Description
Product details
VOGLISLOW G3 M 0.3 is a combination medication used to manage type 2 diabetes mellitus. It combines three active ingredients: Voglibose (0.3 mg), Glimepiride (3 mg), and Metformin Hydrochloride (500 mg). This combination helps regulate blood sugar levels, providing an effective treatment option for individuals who require multi-action control of their diabetes. Key Ingredients: Voglibose (0.3 mg): A type of alpha-glucosidase inhibitor that slows down carbohydrate absorption in the intestines, reducing post-meal blood glucose spikes. Glimepiride (3 mg): A sulfonylurea, which stimulates the pancreas to release more insulin, helping lower blood sugar levels. Metformin Hydrochloride (500 mg): A biguanide that works by reducing the amount of glucose produced by the liver and improving insulin sensitivity, making the body more effective at utilizing glucose. Key Benefits: Effective Blood Sugar Control: By combining three active agents, VOGLISLOW G3 M 0.3 provides comprehensive control of blood sugar levels in individuals with type 2 diabetes. Reduces Post-Meal Blood Sugar Spikes: Voglibose slows down the absorption of carbohydrates, helping to reduce sudden increases in blood glucose after meals. Enhances Insulin Sensitivity: Metformin improves the body’s response to insulin, promoting better glucose absorption and utilization. Stimulates Insulin Production: Glimepiride encourages the pancreas to release more insulin, further helping to reduce blood sugar levels. How Does It Work? VOGLISLOW G3 M 0.3 works through a multi-faceted approach: Voglibose delays the breakdown and absorption of carbohydrates in the intestines, leading to slower and more controlled rises in blood sugar after eating. Glimepiride stimulates insulin production from the pancreas, which helps in controlling blood sugar levels. Metformin works by decreasing glucose production in the liver and enhancing insulin sensitivity, making it easier for cells to absorb and use glucose. Together, these three actions ensure better glycemic control in patients with type 2 diabetes. Directions for Use: VOGLISLOW G3 M 0.3 should be taken as directed by your healthcare provider. Usually, the medication is taken with meals to reduce gastrointestinal side effects and to enhance the efficacy of Voglibose in controlling post-meal glucose spikes. Do not crush or chew the tablet; swallow it whole with water. Ensure that the dosage and timing are strictly followed as per the doctor\\\\'s advice. Side Effects: Common side effects of VOGLISLOW G3 M 0.3 include: Gastrointestinal issues: Bloating, diarrhea, or abdominal discomfort, particularly due to Metformin. Hypoglycemia: Low blood sugar, especially in combination with other antidiabetic drugs or if meals are skipped. Dizziness or headache: These may occur as the body adjusts to the medication. Skin reactions: In rare cases, rashes or allergic reactions may develop.
